Allergens and Adjuvants in Allergen Immunotherapy for Immune Activation, Tolerance, and Resilience

Allergen immunotherapy (AIT) is the only setting in which a vaccine applied patients allergic exactly to active principle vaccine. Therefore, AIT products need be not effective but also safe. In Europe, for subcutaneous AIT, this has been achieved by allergoid strategy IgE epitopes are destroyed or masked. addition, adjuvants physically precipitate allergen at injection site prevent too rapid systemic distribution. The choice of adjuvant critically shapes efficacy and type immune response injected allergen. contrast TH2-promoting adjuvants, others clearly counteract allergy. Marketed Europe formulated with aluminum hydroxide (alum) (66.7%), microcrystalline tyrosine (16.7%), calcium phosphate (11.1%), TH1 monophosphoryl lipid A (5.6%). European practice, United States mostly nonadjuvanted extracts no allergoids used highlighting regulatory maybe “historic preference.” Sublingual form drops tablets currently worldwide without usually higher safety lower patient adherence than AIT. This article will discuss how modulate treated toward activation, modulation, or—with new developments pipeline—immune resilience. Information Category 1 CME CreditCredit can now obtained, free limited time, reading review articles issue. Please note following instructions.Method Physician Participation Learning Process: core material these activities read issue Journal online JACI: Practice Web site: www.jaci-inpractice.org/. accompanying tests may submitted Fax other copies accepted.Date Original Release: May 1, 2021. Credit obtained courses until April 30, 2022.Copyright Statement: Copyright © 2021-2023. All rights reserved.Overall Purpose/Goal: To provide excellent reviews on key aspects disease those who research, treat, manage disease.Target Audience: Physicians researchers within field disease.Accreditation/Provider Statements Designation: American Academy Allergy, Asthma & Immunology (AAAAI) accredited Accreditation Council Continuing Medical Education (ACCME) continuing medical education physicians. AAAAI designates journal-based activity 1.00 AMA PRA Credit™. should claim credit commensurate extent their participation activity.List Design Committee Members: Erika Jensen-Jarolim, MD, Franziska Roth-Walter, PhD, Galateja Jordakieva, Isabella Pali-Schöll, MDsci, PhD (authors); Robert S. Zeiger, (editor)Learning objectives:1.To appreciate differences an makes (AIT).2.To understand why selection pivotal treatment success.3.To informed about novel adjuvant- vector strategies applicable allergy.Recognition Commercial Support: received external commercial support.Disclosure Relevant Financial Relationships Interests: E. Jensen-Jarolim declares inventorship patents formulation Biomedical International R+D, Vienna, Austria, she shareholder; honoraria presentations from Allergy Therapeutics, AllergoPharma, Bencard, Meda, Roxall, ThermoFisher, Vifor; consultant Advisory Boards Vifor Pharma, Sanofi, previously MediGene, Germany, Novartis, Dr. Schär (ceased). F. Roth-Walter R+D GmbH, Austria. G. Jordakieva relevant conflicts interest. I. Pali-Schöll lectures Bencard Allergie Germany. R. Zeiger instructions. Method accepted. Date 2022. reserved. Overall disease. Target Accreditation/Provider activity. List (editor) Recognition support. Disclosure development vaccines against infectious agents toxins paralleled allergens (allergen [AIT]), historically were regarded as toxins, too.1Platts-Mills T.A. allergy epidemics: 1870-2010.J Clin Immunol. 2015; 136: 3-13Abstract Full Text PDF PubMed Google Scholar Extracts biological sources still today even if we know that extract besides specific molecular contains nonallergenic entities. There some fundamental discrepancies among distinct approaches (Table I).2Castellino Galli Del Giudice Rappuoli Generating memory vaccination.Eur J 2009; 39: 2100-2105Crossref Scopus (40) ScholarTable IThe major between (AIT)CharacteristicVaccine diseasesAllergen immunotherapyTypeProphylacticTherapeuticAdjuvantsYes, most casesYes EU, StatesApplication siteSC, ID, IM, IL, EC, oralSCIT: SC ID States, SLIT: sublingual, EC food only; routes experimental onlyDosesSame doses all applications vaccineStepwise increase maintenance doseInjection schemePrime boost, 3-4 shots, 6 mo later shotTreatments 3-5 y, 4-41 shots depending productMemory boostsSingle booster years later, vaccine.Some induce lifelong memory, like live attenuated vaccinia vaccine2Castellino ScholarNo clear recommendation, repetition whole course boost functionEC, Epicutaneous; intradermal; intralymphatic; intramuscular; SC, subcutaneous. Open table tab First, needs safer. Molecular diagnosis greatly improved selection, making best practice example precision medicine.3Incorvaia C. Al-Ahmad M. Ansotegui Arasi Bachert Bos et al.Personalized medicine treatment: unique unmatched model.Allergy. 2021; 76: 1041-1052Crossref (6) Still, least reaction occurred 2.1% 4316 patients,4Calderon M.A. Vidal Rodriguez Rio P. Just J. Pfaar O. Tabar A.I. al.European Survey Adverse Systemic Reactions Immunotherapy (EASSI): real-life clinical assessment.Allergy. 2017; 72: 462-472Crossref (43) (SCIT). greater concern because react systemically preexisting allergen-specific antibodies effector cells. Consequently, accelerating build-up phase, whereas phase dose stays same over years. shortened rush cluster both, adjuvants. so-called technologies have introduced into manufacturing, chemically denatured, instance, formaldehyde, cyanate, glutaraldehyde.5Jensen-Jarolim Bachmann M.F. Bonini Jacobsen L. Jutel Klimek al.State-of-the-art marketed formulations immunotherapy: position paper Clinical (EAACI).Allergy. 2020; 75: 746-760Crossref (22) Glutaraldehyde, polymerizes monomeric giant aggregates, thereby hiding away epitopes, enlarging distance, thus preventing cross-linking. shortened.6Caruso Brame B. Bagnasco D. Cocconcelli A. Ortolani V. Pravettoni al.Adherence increased phase: retrospective study.Biomed Res Int. 2020 (7328469)Crossref (2) survey SCIT sublingual (SLIT), significantly less associated risk anaphylactic reactions unmodified natural adults (P = .001)4Calderon children.7Rodriguez Sanchez-Machin Eberle al.The paediatric assessment.Pediatr 28: 60-70Crossref (44) Safety, therefore, addresses mechanisms cross-linking effector-cell site. precipitation soluble therapy depot lowers distribution IgE-mediated (Figure A). Most effect, although name (derived Latin word adjuvare—“help”) refers immunostimulatory capacity (see below). presently confer effect II).5Jensen-Jarolim Notably, when alum mice was surgically removed 120 minutes T- B-cell responses comparable animals control group.8Hutchison Benson R.A. Gibson V.B. Pollock A.H. Garside Brewer J.M. Antigen required adjuvanticity.FASEB 2012; 26: 1272-1279Crossref (138) deposition rather measure immunostimulation.Table IIAdjuvants SCITCompoundAbbreviationIntroduced inMarket share, %Mean no. injections yAluminum hydroxideAlum193766.741Microcrystalline tyrosineMCT197016.740.5Calcium phosphateCaP198011.126Monophosphoryl AMPLA19995.612 Second, robust TH2 setting. prophylactic diseases, therapeutic intervention. Because initiate first-time antigen naive cells, de novo built up easily. Numerous mouse models, representing approximation human setting, propose preventive effects easily achieved, successful proof-of-concept models more difficult.9Jensen-Jarolim Outstanding animal studies allergy, II: atopic barrier microbiome immunotherapy.Curr Opin 17: 180-187Crossref (8) reason very robust, requiring application schemes range 3 5 finally establish protective response, it activation allergen, tolerance. consequence, immunomodulatory process vaccination. future, usage recombinant fused viral proteins displayed virus-like particles allow introduction immunization closer vaccines10Sondermann N. Shah-Hosseini K. Henkel Schwalfenberg Mosges Success factors hyposensitization.Allergol Select. 2018; 2: 89-93Crossref and, carrier, possibly time protection virus itself.11Eckl-Dorna Weber Stanek Linhart Ristl Waltl E.E. al.Two grass pollen BM32 induces continuously increasing IgG4 response.EBioMedicine. 2019; 50: 421-432Abstract (9) long duration high frequency directly connected compliance patients,12Musa Arifhodzic Al-Herz W. Compliance affecting respiratory allergies.Hum Vaccin Immunother. 13: 514-517Crossref (27) problem SLIT studies.13Vogelberg Bruggenjurgen Richter H. Real-world evidence tree pollen-induced rhinitis asthma.Patient Prefer Adherence. 14: 817-827Crossref optimal improve leading faster relief symptoms number treatments, result better adherence. basic logarithmically rush, infusion pump, build-up, injections, followed tolerance achieved. trick saturate immunoglobulins exploit them uptake eliciting immediate-type side varying protocols 2 monthly vaccine-like 4 year, recommended It seems plausible aqueous adjuvanted divergent responses, various mechanisms. Allergens exceptional antigens they naturally stimulate characterized formation, upregulation receptors, inflammation composed mast eosinophils, and—in periphery—basophils. Typically, results low exposure. These facilitated background elevated IL-4, IL-13, total levels, combined permeable cutaneous mucosal barriers. decisive steps skewing made entrance sites where disturb epithelial layer via enzymatic function. Activated epithelia release thymic stromal lymphopoietin, initiator cascade, IL-33, involved pruritus amplification inflammatory response. Other such Der p activate pathways ability interact LPS, 13, sensed serum amyloid A1, pattern recognition receptor activates lung.14Smole U. Gour Phelan Hofer Kohler Kratzer al.Serum drives immunity.Nat 21: 756-765Crossref (20) However, extracted mucosa complex mixtures often promote environment synergistic Many laboratories observed actually cognate sensitizing capacity. bring bioactive danger signals important cofactors sensitization process, present environmental pollutants microbiota likely helping adjuvants.15Pointner Bethanis Thaler Traidl-Hoffmann Gilles Ferreira al.Initiating sensitization— source, mechanisms.Clin Transl Allergy. 10: 36Crossref synergize robustly pathways. purpose skew bias cytosolic pathway enhanced cross-presentation IgG production B), vacuolar shift C). Adjuvants market, veterinary applications,16Pali-Scholl DeBoer D.J. Alessandri Seida A.A. Mueller R.S. Formulations patients: candidates horizon.Front 11: 1697Crossref mechanistically combine strategies.5Jensen-Jarolim Immunoactivatory alum, phosphate, tyrosin B) crystals equip strong (exception: chemical modifications; exchange hydroxyl ions groups inhibits crystallization resulting amorphous state aggregation).17HogenEsch O’Hagan D.T. Fox C.B. Optimizing utilization vaccines: you might just get what want.NPJ Vaccines. 3: 51Crossref (113) Formulation supports interaction layers dendritic cell (DC) membranes, shown alum.18Flach T.L. Ng Hari Desrosiers M.D. Zhang Ward S.M. al.Alum membrane lipids essential its adjuvanticity.Nat Med. 2011; 479-487Crossref (277) Via scavenger receptor-mediated endocytosis, lead phagolysosomes, mechanically disrupted.19Hornung Bauernfeind Halle Samstad E.O. Kono Rock K.L. al.Silica salts NALP3 inflammasome through phagosomal destabilization.Nat 2008; 9: 847-856Crossref (1943) escaped subsequently enter pathway, degraded peptides proteasome, loaded onto recycled HLA-I molecules endoplasmic reticulum presented T cells surface (HLA-I presentation pathway). During NALP-inflammasome leads caspase-1 proinflammatory IL-1β IL-18.20Ho N.I. Huis In’t Veld L.G.M. Raaijmakers T.K. Adema G.J. enhancing cells: vaccines?.Front 2874Crossref (76) Alum IL-4 independently IL-13,21Brewer Conacher Hunter C.A. Mohrs Brombacher Alexander Aluminium initiates antigen-specific Th2 absence IL-4- IL-13-mediated signaling.J 1999; 163: 6448-6454PubMed reprogrammed nanoparticle technology.22Orr M.T. Khandhar A.P. Seydoux Liang Gage Mikasa T. al.Reprogramming properties oxyhydroxide technology.NPJ 4: 1Crossref (24) IFN-β signaling induced danger-associated patterns-sensing toll-like (TLR) nucleotide-binding oligomerization domain-containing protein activation.23Kooijman Brummelman van Els Marino Heck A.J.R. Mommen G.P.M. al.Novel identified hydroxide-induced prove monocyte pro-inflammatory preparedness.J Proteomics. 175: 144-155Crossref (17) signal gets amplified improving immunogenicity.24Cabral-Miranda Heath Mohsen M.O. Gomes A.C. Engeroff Flaxman al.Virus-like particle (VLP) plus (MCT) enhance B immunogenicity Plasmodium berghei/vivax.Vaccines (Basel). 5: 10Crossref Of note, belongs fact enforce immunity stage, especially formation block (IgG1 IgG4)25Lichtenstein Ishizaka Norman Sobotka Hill antibody measurements ragweed hay fever. Relationship severity immunotherapy.J Investig. 1973; 52: 472-482Crossref Immune (MPLA), compound derived LPS gram-negative bacteria, exploits TLR4 introduces counteracts bias26Aryan Z. Holgate S.T. Radzioch Rezaei era targeting ancient gatekeepers system: agonists asthma.Int Arch 2014; 164: 46-63Crossref (79) As compared MPLA potency.27Schulke Flaczyk Vogel Gaudenzio Angers Loschner al.MPLA shows diminished comparison LPS.Allergy. 70: 1259-1268Crossref (25) slows down phagolysosomal fusion degradation. presentation. IL-27, IL-10, TNF, IFN-γ, TGF-β, according recent transcriptome analysis during trial.28Starchenka Lineberry Higenbottam Skinner Transcriptome profile early-phase immunotherapy.World Organ 12 (100087)Abstract (5) dose-finding trial, triggered Therapy Ordinance, allowed cumulative used. induction since hallmark independent biomarkers compliance.29Shamji M.H. Kappen J.H. Akdis Knol E.F. Kleine-Tebbe al.Biomarkers monitoring rhinoconjunctivitis asthma: EAACI paper.Allergy. 1156-1173Crossref (179) IgG1 may, variable domain, equally neutralization IgG4. constant domains interactions different FcγRs decide cooperation, inhibition study proposed nasal valid reliable biomarker AIT: inhibited IgE-facilitated binding allergen-IgE complexes correlating IL-10+ (Treg) symptom improvement.30Shamji Abubakar-Waziri Steveling Watchman al.Nasal allergen-neutralizing responses: 143: 1067-1076Abstract IgG4, IgG1, turned macrophages immunoregulatory phenotype, reduced expression activatory FcγRIIa upregulated inhibitory FcγRIIb, addition resulted IL-10 CCL-1 secretion.31Bianchini Ohradanova-Repic Flicker Hufnagl Fischer M.B. al.IgG4 M2a M2b-like phenotype: potential implication tolerance.Allergy. 74: 483-494Crossref (29) therefore beneficial circle, secretion, stimulating production.32Bianchini Karagiannis S.N. role fine tuning cancer.Int Mol Sci. 5017Crossref (10) mechanisms, unfavorable cance